Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P68871: Variant p.Val112Ala

Hemoglobin subunit beta
Gene: HBB
Feedback?
Variant information Variant position: help 112 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Valine (V) to Alanine (A) at position 112 (V112A, p.Val112Ala). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (V) to small size and hydrophobic (A) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Polymorphism: help Genetic variations in HBB are involved in resistance to malaria [MIM:611162]. Hemoglobin S (Hb S), which at homozygosity is responsible for sickle cell anemia, is not associated with any clinical abnormality when heterozygous. At heterozygosity, Hb S confers an increase in protection from life-threatening malaria. Additional variants conferring resistance against severe malaria are hemoglobin C (Hb C) and hemoglobin E (Hb E). Additional information on the polymorphism described.
Variant description: help In Stanmore; O(2) affinity down; unstable. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 112 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 147 The length of the canonical sequence.
Location on the sequence: help LHCDKLHVDPENFRLLGNVL V CVLAHHFGKEFTPPVQAAYQ The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 147 Hemoglobin subunit beta
Domain 3 – 147 Globin
Binding site 93 – 93 proximal binding residue
Site 96 – 96 Not glycated
Site 111 – 112 (Microbial infection) Cleavage; by N.americanus apr-2
Modified residue 94 – 94 S-nitrosocysteine
Glycosylation 121 – 121 N-linked (Glc) (glycation) lysine
Helix 102 – 119



Literature citations
A new unstable and low oxygen affinity hemoglobin variant: Hb Stanmore [beta 111(G13)Val-->Ala].
Como P.F.; Wylie B.R.; Trent R.J.; Bruce D.; Volpato F.; Wilkinson T.; Kronenberg H.; Holland R.A.B.; Tibben E.A.;
Hemoglobin 15:53-65(1991)
Cited for: VARIANT STANMORE ALA-112;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.